Healthcare provider profile · identity verified

Linda Chen, DO

Family Practice · OAK PARK, IL · NPI 1093974792

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	317	102
Amlodipine Besylate	Amlodipine Besylate	271	85
Losartan Potassium	Losartan Potassium	131	37
Hydrochlorothiazide	Hydrochlorothiazide	118	37
Levothyroxine Sodium	Levothyroxine Sodium	113	33
Metoprolol Succinate	Metoprolol Succinate	95	32
Rosuvastatin Calcium	Rosuvastatin Calcium	93	29
Metformin Hcl	Metformin Hcl	91	31
Lisinopril	Lisinopril	90	26
Gabapentin	Gabapentin	78	36
Escitalopram Oxalate	Escitalopram Oxalate	67	20
Omeprazole	Omeprazole	61	28
Albuterol Sulfate Hfa	Albuterol Sulfate	54	35
Trazodone Hcl	Trazodone Hcl	51	18
Alendronate Sodium	Alendronate Sodium	50	15
Tizanidine Hcl	Tizanidine Hcl	49	23
Glimepiride	Glimepiride	47	14
Duloxetine Hcl	Duloxetine Hcl	46	14
Fluticasone Propionate	Fluticasone Propionate	45	20
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	45	suppressed
Sertraline Hcl	Sertraline Hcl	45	14
Clonazepam	Clonazepam	43	suppressed
Montelukast Sodium	Montelukast Sodium	41	13
Carvedilol	Carvedilol	39	11
Furosemide	Furosemide	39	15
Tramadol Hcl	Tramadol Hcl	38	13
Pantoprazole Sodium	Pantoprazole Sodium	36	14
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	35	29
Prednisone	Prednisone	34	21
Tamsulosin Hcl	Tamsulosin Hcl	34	12
Breo Ellipta	Fluticasone/Vilanterol	33	suppressed
Potassium Chloride	Potassium Chloride	32	13
Zolpidem Tartrate	Zolpidem Tartrate	32	suppressed
Pravastatin Sodium	Pravastatin Sodium	30	11
Alprazolam	Alprazolam	29	suppressed
Benazepril Hcl	Benazepril Hcl	28	suppressed
Eliquis	Apixaban	27	suppressed
Azithromycin	Azithromycin	26	19
Metformin Hcl Er	Metformin Hcl	26	suppressed
Bupropion Xl	Bupropion Hcl	24	suppressed
Lorazepam	Lorazepam	24	suppressed
Donepezil Hcl	Donepezil Hcl	23	suppressed
Enalapril Maleate	Enalapril Maleate	23	suppressed
Simvastatin	Simvastatin	23	suppressed
Jardiance	Empagliflozin	22	suppressed
Famotidine	Famotidine	21	11
Allopurinol	Allopurinol	20	suppressed
Chlorthalidone	Chlorthalidone	19	suppressed
Diclofenac Sodium	Diclofenac Sodium	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	19	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	19	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Valsartan	Valsartan	19	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Glipizide	Glipizide	18	suppressed
Lovastatin	Lovastatin	18	suppressed
Meloxicam	Meloxicam	18	suppressed
Telmisartan	Telmisartan	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	15
Valacyclovir	Valacyclovir Hcl	17	12
Meclizine Hcl	Meclizine Hcl	16	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	16	suppressed
Naproxen	Naproxen	15	suppressed
Nebivolol Hcl	Nebivolol Hcl	15	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	15	suppressed
Trulicity	Dulaglutide	14	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	13	suppressed
Fluconazole	Fluconazole	13	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Irbesartan	Irbesartan	13	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	13	12
Amitriptyline Hcl	Amitriptyline Hcl	12	suppressed
Atenolol	Atenolol	12	suppressed
Clopidogrel	Clopidogrel Bisulfate	12	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	12	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Linzess	Linaclotide	11	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	11	suppressed
Vascepa	Icosapent Ethyl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error